Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
KRYSTEXXA 8MG is a federal award for 245-Network Contract Office 5 (36C245) held by Horizon Therapeutics Usa, Inc. Estimated value $132K ($132K obligated). Current period of performance ends Jan 28, 2022. Last award drew 1 bidder. Place of performance: LA VERGNE TN.
Recompete timing
PublicCurrent PoP ended Jan 28, 2022 (1667 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C24522N0278?
36C24522N0278 (Krystexxa 8mg) is a 245-Network Contract Office 5 (36C245) award with a potential value of $132K, currently held by Horizon Therapeutics Usa, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C245-22-N-0278?
36C245-22-N-0278 is the dashed form of PIID 36C24522N0278 (Krystexxa 8mg), held by Horizon Therapeutics Usa, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C24522N0278?
245-Network Contract Office 5 (36C245) awarded 36C24522N0278 to Horizon Therapeutics Usa, Inc (potential $132K).
Who is the incumbent on 36C24522N0278?
Horizon Therapeutics Usa, Inc is the incumbent. The current period of performance ends Jan 28, 2022.
When does Horizon Therapeutics Usa, Inc’s 36C24522N0278 come up for recompete?
SCOUT tracks a period-of-performance end of Jan 28, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.